Arlene Siefker-Radtke, MD, is a board-certified medical oncologist who currently serves as Professor and Co-Leader of the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer in Houston, Texas.
Based on her expertise in genitourinary cancer, Dr Siefker-Radtke serves in multiple leadership roles including: Chair of the Steering Committee for the PIVOT-10 Clinical Trial by Nektar; Clinical Co-Leader of the Bladder SPORE Executive Committee at The University of Texas MD Anderson Cancer Center; Disease Site Liaison of the International Center at The University of Texas MD Anderson Cancer Center; Advisory Board member of the PanCanadian Urachal Cancer Study Urachal Tumour DNA Sequencing Project, Urachal Cancer Research Fund, Jewish General Hospital Foundation (Canada); Panelist for the Bladder Cancer and Penile Cancer Clinical Practice Guidelines in Oncology Committees at the National Comprehensive Cancer Network; Bladder Cancer Task Force at the National Cancer Institute; and Genitourinary Committee member for the SWOG Network.
She is an active member of the American Society of Clinical Oncology, the American Association for Cancer Research, the American Urological Association, the SWOG Network, and the Society of Urologic Oncology. Dr Siefker-Radtke has authored or coauthored at least 86 peer-reviewed journal articles and at least 18 book chapters. She serves as an ad hoc reviewer for at least 15 peer-reviewed journals. Dr Siefker-Radtke’s clinical research focuses on genitourinary malignancies.